Ozanimod Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Ozanimod Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
56
Registered trials
138
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Ozanimod Hydrochloride can convert its Small molecule drug profile and S1PR1 x S1PR5 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Ozanimod Hydrochloride (query alias: Ozanimod Hydrochloride) |
|---|---|
| Modality / target | Small molecule drug; S1PR1 x S1PR5; S1PR1 modulators, S1PR5 modulators |
| Highest global status | Approved |
| Originator | The Scripps Research Institute |
| Active developers | Celgene International II SARL, Celgene Corp., Celgene Pharmaceuticals Information Consulting Co., Ltd. |
The MCP disease footprint includes Colitis, Ulcerative, Multiple sclerosis relapse, Multiple Sclerosis, Relapsing-Remitting. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| JPRN-jRCT1031250583 | Not Applicable | 募集中 | 150 | Proportion of patients achieving steroid-free symptomatic remission at Week 12 |
| NCT07271069 | Not Applicable | Recruiting | 150 | Proportion of participants achieving steroid-free symptomatic remission |
| IRCT20200623047902N46 | Not Applicable | Recruiting | 24 | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase 4, Prospective, Open-label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants With Moderate to Severe Ulcerative Colitis in Clinical Practice
Phase 4; n=139; evaluation: not stated. Reported fields: Observed Cases = 65.8 Percent of Participants (95% Confidence Interval, 54.0 - 76.3); -; -
Preliminary Baseline Characteristics and Early Follow-up in the COAST Study: Anti-CD20 to Ozanimod Sequencing Trial
Not Applicable; n=23; evaluation: Positive. Reported fields: Serious infections = 1.0 Pts
P042. Relationship Between Neurofilament Light Chain Levels and Radiologic Outcomes in Patients With Early Relapsing Multiple Sclerosis in the Phase 3b ENLIGHTEN Trial of Ozanimod: 3-Year Results
Phase 3; n=157; evaluation: Positive. Reported fields: NfL levels(baseline) = 13.9 pg/mL
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Ozanimod Hydrochloride addresses Colitis, Ulcerative, Multiple sclerosis relapse, Multiple Sclerosis, Relapsing-Remitting. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-09-05 | Zydus ties up with Synthon BV for multiple sclerosis drug launch in US | Approved | Financial terms not disclosed |
| 2015-07-14 | Receptos founder returns with ShouTi and $100M for oral drugs to treat chronic diseases | Not disclosed | US$720.0M stated total |
| 2009-01-01 | The U.S. Food and Drug Administration has approved ozanimod, an immune-modulating therapy invented at Scripps Research | Not disclosed | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Ozanimod hydrochloride capsule and preparation method thereof”. The milestone feed surfaced a patent-application signal described as “Crystalline forms of ozanimod hydrochloride”. The milestone feed surfaced a patent-application signal described as “Polymorphic forms of ozanimod hydrochloride”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
